Met is a prognostic indicator of colorectal cancer patient survival. Therapies that target Met may therefore have beneficial outcomes in the clinic. Recently, EGCG was reported to suppress Met activation, although the mechanisms were not elucidated. HCT116 and HT29 human colon cancer cells were used to examine the relationships between...